263 related articles for article (PubMed ID: 3856076)
21. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies.
Yoshikawa T; Nishida K; Tanigawa M; Fukumoto K; Kondo M
Digestion; 1985; 31(2-3):67-76. PubMed ID: 2581838
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer.
Marrelli D; Pinto E; De Stefano A; Farnetani M; Garosi L; Roviello F
Am J Surg; 2001 Jan; 181(1):16-9. PubMed ID: 11248169
[TBL] [Abstract][Full Text] [Related]
23. [Assay of serum carbohydrate antigen (CA) 19-9 in the diagnosis of gastric cancer].
Nishida K; Yamamoto T; Yoshioka K; Iida M; Miyagawa H; Yoshikawa T; Sugino S; Kondo M
Gan To Kagaku Ryoho; 1986 Jan; 13(1):101-8. PubMed ID: 3455804
[TBL] [Abstract][Full Text] [Related]
24. Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer.
Safi F; Kuhns V; Beger HG
Int J Biol Markers; 1995; 10(2):100-6. PubMed ID: 7561233
[TBL] [Abstract][Full Text] [Related]
25. Gastrointestinal cancer follow-up: the effectiveness of sequential CEA, TPA and Ca 19-9 evaluation in the early diagnosis of recurrences.
Barillari P; Sammartino P; Cardi M; Ricci M; Gozzo P; Cesareo S; Cerasi A
Aust N Z J Surg; 1991 Sep; 61(9):675-80. PubMed ID: 1877936
[TBL] [Abstract][Full Text] [Related]
26. [Experiences with determining carcinoembryonic antigen in tumors of the digestive tract].
Pelikán A
Zentralbl Chir; 1986; 111(18):1113-8. PubMed ID: 3024422
[TBL] [Abstract][Full Text] [Related]
27. Prospective evaluation of the diagnostic efficacy of CA 19-9 assay as a marker for gastrointestinal cancers.
Andriulli A; Gindro T; Piantino P; Farini R; Cavallini G; Piazzi L; Naccarato R; Dobrilla G; Verme G; Scuro LA
Digestion; 1986; 33(1):26-33. PubMed ID: 3940235
[TBL] [Abstract][Full Text] [Related]
28. [Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen in gastrointestinal neoplasms. Comparison of markers].
Capocasale E; Contini S; Rossetti A; Del Sante G; Gregori G
Acta Biomed Ateneo Parmense; 1985; 56(6):231-6. PubMed ID: 2940782
[TBL] [Abstract][Full Text] [Related]
29. [The doubling time of circulating CEA as an individual prognostic criterion of recurrence in patients with gastrointestinal cancers].
Brümmendorf T; Anderer FA; Staab HJ; Hornung A; Kieninger G
Klin Wochenschr; 1986 Jan; 64(2):63-9. PubMed ID: 3951166
[TBL] [Abstract][Full Text] [Related]
30. [Comparison between the gastrointestinal tumor antigen and the carcinoembryonic antigen in diseases of the digestive tract].
Tappero G; Piantino P; Cerchier A; Pecchio F
Minerva Med; 1985 Apr; 76(16):765-70. PubMed ID: 2582313
[TBL] [Abstract][Full Text] [Related]
31. Carcinoembryonic antigen slope analysis as an early indicator for recurrence of colorectal carcinoma.
Kimura O; Kaibara N; Nishidoi H; Okamoto T; Takebayashi M; Kawasumi H; Koga S
Jpn J Surg; 1986 Mar; 16(2):106-11. PubMed ID: 3723883
[TBL] [Abstract][Full Text] [Related]
32. Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125.
Szymendera JJ
Tumour Biol; 1986; 7(5-6):333-42. PubMed ID: 2437641
[TBL] [Abstract][Full Text] [Related]
33. [Clinical significance of the circulating tumor-associated antigen CA 19-9 in cancers of the digestive tract].
Staab HJ; Hornung A; Anderer FA; Kieninger G
Dtsch Med Wochenschr; 1984 Jul; 109(30):1141-7. PubMed ID: 6204834
[TBL] [Abstract][Full Text] [Related]
34. Clinical evaluation of the new tumor marker TAG-72.
Guadagni F; Roselli M; Ferroni P; Amato T; Colcher D; Greiner JW; Schlom J
Anticancer Res; 1991; 11(4):1389-94. PubMed ID: 1746895
[TBL] [Abstract][Full Text] [Related]
35. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer.
Benini L; Cavallini G; Zordan D; Rizzotti P; Rigo L; Brocco G; Perobelli L; Zanchetta M; Pederzoli P; Scuro LA
Pancreas; 1988; 3(1):61-6. PubMed ID: 3163149
[TBL] [Abstract][Full Text] [Related]
36. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
[TBL] [Abstract][Full Text] [Related]
37. [Diagnosis and treatment of colorectal cancer using monoclonal antibodies].
Inagi H; Okuda H; Shimano T; Kadota T; Mori T
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2291-7. PubMed ID: 3460528
[TBL] [Abstract][Full Text] [Related]
38. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
Kuusela P; Haglund C; Roberts PJ; Jalanko H
Br J Cancer; 1987 Jun; 55(6):673-6. PubMed ID: 2441731
[TBL] [Abstract][Full Text] [Related]
39. The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
Staab HJ
Acta Gastroenterol Belg; 1987; 50(1):29-35. PubMed ID: 3480668
[No Abstract] [Full Text] [Related]
40. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
